Phase I Study of the Pharmacokinetics and Pharmacodynamics of ZD6474 in Combination With Docetaxel in Advanced Solid Tumors.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 26 Apr 2017
At a glance
- Drugs Vandetanib (Primary) ; Docetaxel
- Indications Advanced breast cancer; Head and neck cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
- Focus Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 06 Jan 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 15 Jul 2009 New trial record